|
||
| |||||||
|
Peakdale establishes in-house computational chemistry capabilities
Chapel-en-le-Frith, UK, July 19,
2005 – Peakdale Molecular announces the establishment of its in-house
computational chemistry expertise and the appointment of Dr Steven Enoch to
head the department and drive Peakdale’s in-house capabilities. Dr Enoch
brings specialist structure-based design knowledge and application to the
team, which will play a vital role in developing drug-like compounds,
complementing the Company’s innovative chemistry expertise.
Dr Enoch joins Peakdale from Cyprotex Discovery,
where he played a key role as a chemoinformatician. During his time at
Cyprotex he provided QSPR models for customers and was part of a research team
that developed novel QSPR building techniques. Previous to this he completed
an MSc in chemoinformatics at the University of Sheffield, which included a
3-month project with GlaxoSmithKline, and a PhD in computational inorganic
chemistry at Heriot-Watt University, Edinburgh.
With computational chemistry facilities in-house,
Peakdale will build on its existing Peakexplorer™ libraries for drug
discovery, with the focus currently on designing Kinase libraries. The Company
uses the Schrödinger software system, which is capable of research using the
latest ligand and structure based design methods. Steven brings expert
knowledge in pharmacophore generation, virtual screening, and library design,
which, in combination with the Schrödinger software, will help design novel
compounds outside of existing chemical space.
Speaking on his appointment, Peakdale CEO,
Kimberley Morrison said, “Steven’s appointment represents the next stage in
Peakdale’s expansion and signifies an important step for us. Having in-house
computational capabilities means that we can build on our existing reputation
for delivering novel compounds and key intermediates and offer further
services to our customers.”
Steven added, “It has long been my ambition to
have a role where my input can help guide the synthesis and development of new
compounds. I’m very pleased to have joined a Company with such a good
reputation for innovation, and in my role of driving Peakdale’s computational
chemistry capabilities I intend to carry on this ethic."
About Peakdale Molecular Ltd: Peakdale Molecular was founded in 1992. Today, the Company’s customers include global pharmaceutical majors and an increasing number of biotechnology companies. Its team of chemists combines experience in pharmaceutical R&D and process development, fine chemicals, parallel synthesis and medicinal chemistry to deliver unique chemistry solutions to a range of drug discovery challenges. Peakdale operates in several distinct markets providing novel screening compounds, targeted screening libraries, catalogue intermediates, custom synthesis and contract research chemistry. Further information about the Company can be obtained at www.peakdale.co.uk.
For more information please contact:
At the Company Kim Morrison, CEO +44 (0)1298 816700 kim.morrison@peakdale.co.uk On behalf of the Company Marc Egelhofer, Northbank Communications +44 (0)1260 296500 m.egelhofer@northbankcommunications.com
|
|
| ||||||||
